AFIMMUNE LIMITED

Afimmune Limited is a Dublin‑based drug discovery and development company dedicated to creating new medicines for people living with rare and inflammatory diseases. By advancing assets through both pre‑clinical and clinical stages, the firm aims to translate cutting‑edge science into therapies that improve quality of life for patients with unmet medical needs.

The company’s pipeline features novel biologics and small‑molecule candidates, including a second‑generation synthetic W‑3 fatty acid, EPELEUTON, which has demonstrated protective effects against organ damage in humanised sickle‑cell mouse models. Afimmune recently completed enrolment in its first clinical trial for sickle‑cell disease and is set to present the findings at the 67th American Society of Hematology (ASH) Annual Meeting, underscoring its commitment to bringing rare‑disease therapeutics from bench to bedside.

With a focus on rare‑disease therapeutics, Afimmune serves patients, clinicians and research partners worldwide, leveraging its expertise in biopharmaceutical development to address conditions that currently lack effective treatment options.